ATG16L1 and neoplasm: To evaluate whether ATG16L1 expression is associated with response to ICI in non-MSI CRC, we evaluated tumor gene expression data from IMblaze370 (NCT02788279), a large (n = 363) multi-center phase III trial in locally advanced or metastatic CRC where disease progression was observed in at least two previous lines of chemotherapy33.